In recent trading session, Astrazeneca plc ADR (NASDAQ:AZN) saw 1.49 million shares changing hands at last check today with its beta currently measuring 0.41. Company’s recent per share price level of $68.92 trading at -$0.63 or -0.91% at last check today assigns it a market valuation of $213.74B. That most recent trading price of AZN’s stock is at a discount of -27.22% from its 52-week high price of $87.68 and is indicating a premium of 11.14% from its 52-week low price of $61.24. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 5.22 million shares which gives us an average trading volume of 6.06 million if we extend that period to 3-months.
For Astrazeneca plc ADR (AZN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.38. Splitting up the data highlights that, out of 10 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 8 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 1.11 in the current quarter.
Astrazeneca plc ADR (NASDAQ:AZN) trade information
Upright in the red during last session for losing -0.91%, in the last five days AZN remained trading in the green while hitting it’s week-highest on Thursday, 04/24/25 when the stock touched $68.92 price level, adding 1.13% to its value on the day. Astrazeneca plc ADR’s shares saw a change of 5.19% in year-to-date performance and have moved 1.97% in past 5-day. Astrazeneca plc ADR (NASDAQ:AZN) showed a performance of -5.23% in past 30-days. Number of shares sold short was 10.6 million shares which calculate 1.9 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 88 to the stock, which implies a rise of 21.68% to its recent value today. Analysts have been projecting 88 as a low price target for the stock while placing it at a high target of 88. It follows that stock’s current price would drop -27.68% in reaching the projected high whereas dropping to the targeted low would mean a loss of -27.68% for stock’s current value.
Astrazeneca plc ADR (AZN) estimates and forecasts
This year revenue growth is estimated to rise 6.26% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 13.71B for the same. And 8 analysts are in estimates of company making revenue of 14.03B in the next quarter. Company posted 12.68B and 12.94B of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 34.63% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 9.35% while estimates for its earnings growth in next 5 years are of 11.02%.
AZN Dividends
Astrazeneca plc ADR is more likely to be releasing its next quarterly report on 2025-Feb-05 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 2.25%, the share has a forward dividend of 1.55 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 2.29%.
Astrazeneca plc ADR (NASDAQ:AZN)’s Major holders
Insiders are in possession of 0.00% of company’s total shares while institution are holding 17.49 percent of that, with stock having share float percentage of 17.49%. Investors also watch the number of corporate investors in a company very closely, which is 17.49% institutions for Astrazeneca plc ADR that are currently holding shares of the company. PRICE T ROWE ASSOCIATES INC /MD/ is the top institutional holder at AZN for having 64.94 million shares of worth $5.06 billion. And as of 2024-06-30, it was holding 4.1788 of the company’s outstanding shares.
The second largest institutional holder is PRIMECAP MANAGEMENT CO/CA/, which was holding about 42.6 million shares on 2024-06-30. The number of shares represents firm’s hold over 2.7411 of outstanding shares, having a total worth of $3.32 billion.
On the other hand, VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund and WASHINGTON MUTUAL INVESTORS FUND are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 25.51 shares of worth $1.77 billion or 0.97% of the total outstanding shares. The later fund manager was in possession of 20.06 shares on Mar 31, 2025 , making its stake of worth around $1.39 billion in the company or a holder of 0.76% of company’s stock.
